Cognoa
Overview
Cognoa develops artificial intelligence and machine learning solutions for early detection and assessment of neurodevelopmental conditions, particularly autism spectrum disorder in children. The company leverages digital biomarkers and behavioral analysis to provide clinicians and families with objective diagnostic tools and clinical decision support.
More in Neurotechnology
Latest industry news
FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach
2026-07-09 · Policy
Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans
2026-07-08 · Policy
University of Michigan Completes First Long-Term Wireless Brain-Computer Interface Implant in Humans
2026-07-07 · Research
Synchron Closes $275M Series E to Accelerate Stentrode BCI Commercialization
2026-06-29 · Funding
Company details
Category
🏢 Neurotechnology
Funding
Private
Listed
2026-07-10
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →